What are the common side effects of diabetes medications?

Side Effects of Diabetic Drugs

Each class of diabetes medication has a distinct side effect profile that should guide drug selection, with metformin causing primarily gastrointestinal issues, sulfonylureas and insulin causing hypoglycemia and weight gain, GLP-1 agonists causing nausea, SGLT2 inhibitors causing genitourinary infections, and thiazolidinediones causing fluid retention and fractures. 1, 2

Metformin (First-Line Agent)

Gastrointestinal side effects are the most common issue:

• Bloating, abdominal discomfort, and diarrhea
• Can be mitigated by gradual dose titration or using extended-release formulation 2, 3

Vitamin B12 deficiency:

• Occurs with long-term use
• Can worsen neuropathy symptoms
• Requires periodic monitoring and supplementation if deficient 2, 1, 3

Lactic acidosis:

• Extremely rare complication
• Risk increases with eGFR <30 mL/min/1.73 m²
• Should be discontinued during severe illness, vomiting, dehydration, or before contrast imaging 1, 4, 3

Sulfonylureas

Hypoglycemia is the primary concern:

• Dose-related risk
• Higher risk in elderly patients and those with liver/kidney disease
• Risk increases 50% when combined with DPP-4 inhibitors 1, 4
• Glipizide, glimepiride, and gliclazide may have lower hypoglycemia risk compared to other sulfonylureas 1

Weight gain:

• Relatively modest (1-5 kg) in large cohort studies 1

Cardiovascular concerns:

• Some observational studies suggest adverse cardiovascular outcomes, though findings are inconsistent 1

GLP-1 Receptor Agonists

Gastrointestinal effects are most common:

• Nausea, vomiting (frequent at treatment initiation)
• Usually improve over time 1

Rare but serious concerns:

• Pancreatitis (rare but increased rates reported)
• Possible thyroid C-cell tumors (based on animal studies)
• Pancreatic cancer risk not definitively ruled out 1

Hypoglycemia:

• Minimal risk when used alone
• Increases hypoglycemic potential when combined with insulin or sulfonylureas 1

SGLT2 Inhibitors

Genitourinary infections:

• Increased risk of genital mycotic infections
• Urinary tract infections 1

Volume depletion issues:

• Acute kidney injury
• Dehydration
• Orthostatic hypotension
• Use caution when combined with diuretics, ACE inhibitors, or ARBs 1

Diabetic ketoacidosis:

• Rare but concerning, especially in insulin-deficient patients
• Requires patient education 1

Canagliflozin-specific concerns:

• Lower-limb amputation (6.3 vs 3.4 per 1,000 patient-years; HR 1.97)
• Fracture risk (15.4 vs 11.9 per 1,000 patient-years; HR 1.26)
• Uncertain if these are class effects 1

DPP-4 Inhibitors

Generally well-tolerated with neutral weight effect 1

Hypoglycemia:

• Minimal risk as monotherapy
• Risk increases 50% when added to sulfonylureas 1

Rare but notable:

• Pancreatitis (rare but increased rates)
• Musculoskeletal side effects
• Anaphylactic reactions, Stevens-Johnson syndrome (rare) 1

Heart failure concerns:

• Saxagliptin and alogliptin showed imbalances in heart failure rates in cardiovascular outcome trials 1

Renal dosing:

• Most require dose adjustment based on renal function
• Linagliptin is the exception (minimal renal excretion) 1

Thiazolidinediones (TZDs)

Fluid retention and heart failure:

• Major safety concern
• Contraindicated in patients with heart failure 1

Weight gain:

• Significant issue
• Can be mitigated with lower doses (e.g., pioglitazone 15-30 mg) 1

Bone fractures:

• Increased risk, particularly in women 1

Bladder cancer:

• Possible association (particularly with pioglitazone) 1

Insulin

Hypoglycemia:

• Most significant risk
• Severe hypoglycemia incidence higher than with sulfonylureas 1

Weight gain:

• Consistent finding with insulin therapy 3, 5

Possible cancer risk:

• Cannot be ruled out that insulin may increase risk of certain cancers 1

Alpha-Glucosidase Inhibitors

Gastrointestinal disorders:

• Bloating, flatulence, diarrhea
• Often limit tolerability and adherence 6

Key Clinical Pitfalls to Avoid

1. Don't continue metformin during acute illness - Hold during severe illness, dehydration, or before contrast studies 1, 4

2. Monitor vitamin B12 with long-term metformin use - Especially in patients with anemia or neuropathy 2, 1, 3

3. Adjust DPP-4 inhibitor doses for renal function - Except linagliptin 1

4. Avoid TZDs in heart failure patients - Fluid retention can precipitate or worsen heart failure 1

5. Educate SGLT2 inhibitor patients about ketoacidosis - Particularly those with insulin deficiency 1

6. Be cautious combining drugs that cause hypoglycemia - Sulfonylureas or insulin with GLP-1 agonists or DPP-4 inhibitors 1